Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors

被引：0
作者：
Berardi, R. [1 ]
Torniai, M. [1 ]
Pusceddu, S. [2 ]
Spada, F. [3 ]
Brizzi, M. P. [4 ]
Ibrahim, T. [5 ]
Antonuzzo, L. [6 ]
Ferolla, P. [7 ]
Panzuto, F. [8 ]
Silvestris, N. [9 ]
Partelli, S. [10 ]
Bongiovanni, A. [5 ]
Zichi, C. [4 ]
Riva, N. [5 ]
Rinzivillo, M. [8 ]
机构：
[1] Univ Politecn Marche, Ancona, Italy
[2] INT, Milan, Italy
[3] IEO, Milan, Italy
[4] San Luigi Hosp, Orbassano, Italy
[5] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[6] AOU Careggi, Florence, Italy
[7] Osped S Maria Misericordia, Perugia, Italy
[8] Sapienza Univ Rome, St Andrea Hosp, Sch Med, Rome, Italy
[9] Cancer Inst Giovanni Paolo II, Bari, Italy
[10] Univ Vita & Salute, Osped San Raffaele IRCCS, Milan, Italy
来源：
NEUROENDOCRINOLOGY | 2016年 / 103卷
关键词：
PNET; Dose intensity; Targeted therapy; Everolimus; Cumulative dose;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
L2
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [31] Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea
    Kyong Joo Lee
    Jae Hee Cho
    Sang Hyub Lee
    Si Young Song
    Kwang Hyuk Lee
    Seok Jeong
    Ji Kon Ryu
    Sang Myung Woo
    Seungmin Bang
    Jong Kyun Lee
    Tae Hoon Lee
    Woo Hyun Paik
    Yong Tae Kim
    Woo Jin Lee
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 799 - 805
  • [32] Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177Lu-octreotate
    Kamp, Kimberly
    Gumz, Brenda
    Feelders, Richard A.
    Kwekkeboom, Dik J.
    Kaltsas, Gregory
    Costa, Frederico P.
    de Herder, Wouter W.
    ENDOCRINE-RELATED CANCER, 2013, 20 (06) : 825 - 831
  • [33] Everolimus in the Treatment of Neuroendocrine Tumors: Lights and Shadows
    Medici, Bianca
    Caffari, Eugenia
    Maculan, Yuri
    Benatti, Stefania
    Piacentini, Federico
    Dominici, Massimo
    Gelsomino, Fabio
    BIOMEDICINES, 2025, 13 (02)
  • [34] Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors
    Kawaguchi, Yoshiaki
    Maruno, Atsuko
    Kawashima, Yohei
    Ito, Hiroyuki
    Ogawa, Masami
    Mine, Tetsuya
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (42) : 15920 - 15924
  • [35] Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)
    Vernieri, Claudio
    Pusceddu, Sara
    Fuca, Giovanni
    Indelicato, Pietro
    Centonze, Giovanni
    Castagnoli, Lorenzo
    Ferrari, Elisa
    Ajazi, Arta
    Pupa, Serenella
    Casola, Stefano
    Foiani, Marco
    Mazzaferro, Vincenzo
    Pruneri, Giancarlo
    Milione, Massimo
    de Braud, Filippo
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (07) : 1704 - 1712
  • [36] A Real-world Multicenter Prospective Study of Everolimus in Pancreatic Neuroendocrine Tumors: The 'PROTOR' Study
    Kaltsas, Gregory
    Andreadis, Charalambos
    Kosmidis, Paraskevas
    Mavroudis, Dimitrios
    Pazaitou-Panayiotou, Kalliopi
    Vaslamatzis, Michail
    Athanasiadis, Ilias
    ANTICANCER RESEARCH, 2022, 42 (04) : 1941 - 1948
  • [37] Metastatic Pancreatic Neuroendocrine Tumors with Ectopic Cushing Syndrome: Could Everolimus Be a Safe Therapeutic Option?
    Davi, M., V
    Cingarlini, S.
    Butturini, G.
    Capelli, P.
    Scarpa, A.
    Francia, G.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 295 - 295
  • [38] Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea
    Lee, Kyong Joo
    Cho, Jae Hee
    Lee, Sang Hyub
    Song, Si Young
    Lee, Kwang Hyuk
    Jeong, Seok
    Ryu, Ji Kon
    Woo, Sang Myung
    Bang, Seungmin
    Lee, Jong Kyun
    Lee, Tae Hoon
    Paik, Woo Hyun
    Kim, Yong Tae
    Lee, Woo Jin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 799 - 805
  • [39] Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment
    D'Onofrio, Mirko
    Cingarlini, Sara
    Ortolani, Silvia
    Crosara, Stefano
    De Robertis, Riccardo
    Vallerio, Paola
    Grego, Elisabetta
    Ciaravino, Valentina
    Ruzzenente, Andrea
    Landoni, Luca
    Scarpa, Aldo
    Bassi, Claudio
    Tortora, Giampaolo
    ANTICANCER RESEARCH, 2017, 37 (03) : 1305 - 1311
  • [40] Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors
    Yoshiaki Kawaguchi
    Atsuko Maruno
    Yohei Kawashima
    Hiroyuki Ito
    Masami Ogawa
    Tetsuya Mine
    World Journal of Gastroenterology, 2014, (42) : 15920 - 15924
12345